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Biliary malignancies: modest gains, residual strains
Over the past two decades, dramatic changes have occurred
in medicine and, in particular, in the field of hepatopan-
creatobiliary diseases. With respect to cancer, the role that
oncogenes and tumour suppressor genes play in pathogene-
sis has become apparent. With respect to imaging,
computerised tomography (CT), magnetic resonance imag-
ing (MRI) and positron emission tomography (PET) have
all evolved substantially. Similarly, interventional radiology
and endoscopy have come of age. At the same time, the
ability to perform safe liver surgery and transplantation has
become routine. In addition, major advances have occurred
in the more focal delivery of radiotherapy as well as in the
modes of delivery and in the array of available chemother-
apeutic agents. Despite these major advances, the overall
outcome of patients with gallbladder and bile duct malig-
nancies has not changed significantly over the same time
period.
During the 1980s and 1990s, major changes occurred in
world communications. The acceptance of one language in
which to communicate at international meetings, the
introduction of fax and, of course, the development of the
internet have been great advances. Nevertheless, our abil-
ity to communicate effectively about biliary malignancies
continues to be hampered by confusion in classification.
For all malignancies, we have at least three staging systems,
the American (AJCC), the European (UICC) and the
Japanese. Moreover, for biliary malignancies, we have mul-
tiple individual systems, such as the Bismuth classification,
which stratifies tumours by perihilar bile duct involvement
and the new Memorial tumour classification, which
includes vascular encasement. However, both of these
systems ignore intrahepatic (peripheral) and distal bile duct
tumours as well as lymph node and distant metastases. In
addition, tumours that begin in the gallbladder and sec-
ondarily involve the bile duct are often included with
cholangiocarcinomas. Agreement on and consistent appli-
cation of one classification system will be necessary for us
to make progress in the future.
Another major factor that inhibits progress in our
understanding and treatment of biliary malignancies is
their relative rarity. In most parts of the world gallbladder
cancer occurs in only 2–3/100 000 individuals. Interestingly,
data from both the USA and the UK suggest that the
incidence of cholangiocarcinoma may be increasing.
However, this apparent increase may only represent an
improved ability to differentiate cholangiocarcinoma from
advanced gallbladder cancer. Nevertheless, the fact that
both bile duct and gallbladder cancers are (1) uncommon
compared with hepatocellular and pancreatic cancer and
(2) very rare compared with breast, prostate, lung and
colon cancer has inhibited our progress. Nevertheless, the
opportunity exists to focus on areas of high incidence such
as north-east Thailand, India, Chile, West Virginia and
New Mexico to learn more about these rare malignancies.
Similarly, further study of patients with premalignant con-
ditions such as those with an abnormal pancreatobiliary
duct junction, gallbladder polyps, choledochal cysts, intra-
hepatic stones, primary sclerosing cholangitis (PSC) and
inflammatory bowel disease should enhance our knowledge
of the pathogenesis of these malignancies.
During the past 10 years, multiple strategies have
enhanced our knowledge of the pathogenesis of pancreato-
biliary malignancies. These strategies have included the
systematic study of (1) human tumours, (2) cell lines, (3)
familial and high-risk patients and (4) animal models. For
pancreatic cancer, these strategies have led to a progression
hypothesis based on K-ras and Her-2-neu oncogene initia-
tion, subsequent p53 and p21 tumour suppressor gene
inactivations and, in some patients, trypsinogen, DPC4 and
BRAC2 gene alterations. Human biliary tumours also have
been studied, but the frequency of K-ras and Her-2-neu
oncogenes activation is less than with pancreatic tumours,
whereas the p53 tumour suppressor gene does play a role in
approximately 50% of the patients. On the other hand,
recent data from cholangiocarcinomas arising in PSC
patients suggest that p16 tumour suppressor gene over-
expression is much more common than K-ras or p53
abnormalities. However, the systematic study of biliary can-
cer cell lines and high-risk patients as well as the
development of good animal models has occurred at a
slower pace than with pancreatic cancer. In addition, famil-
ial biliary cancer has not been described. Nevertheless, new
gene chip and microarray technologies provide the oppor-
tunity for a quantum leap in our knowledge of the genetic
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pathogenesis of biliary malignancy. With respect to envi-
ronmental risk factors, smoking has been clearly implicated
for pancreatic cancer. For biliary malignancies, radiation
exposure and chemical carcinogens, such as dioxin, may be
key for cancer initiation and progression.
The pathological diagnosis of biliary malignancies can be
quite difficult due, in part, to the relative paucity of cancer
cells. Routine cytology of brushings and small punch biopsies
have a relatively low sensitivity. Adding K-ras and p53
analysis has not been particularly helpful, because both
these markers are present in less than half or about half of
the tumours, respectively. As p16 abnormalities are quite
common, probing biliary epithelial cells for p16 alterations
may be more fruitful. One report suggests that PET scanning
can document the development of cholangiocarcinoma in
patients with PSC. However, further studies of PET scan-
ning in patients at high risk for biliary malignancies need to
be performed. Similarly, more data are required to deter-
mine the value of serum tumour markers such as CEA and
CA-19-9, but the development of a biliary malignancy-
specific tumour marker would be ideal.
The ability of spiral CT with three-dimensional recon-
struction and MR to detect liver metastases and vascular
invasion has improved dramatically. CT and MR cholan-
giography are now available, and MRC has been shown to
be equal to direct cholangiography (endoscopic retrograde
[ERC] or percutaneous transhepatic [PTC]) in detecting
common duct stones. However, the utility of MRC to accu-
rately to define the intrahepatic ductal involvement of biliary
malignancies has yet to be proven. Similarly, the advantage of
staging laparoscopy in patients with more advanced gallblad-
der cancers has been documented. However, the role of
laparoscopy inthe evaluation of patients with early stage gall-
bladder cancer and in those with intrahepatic, perihilar and
distal cholangiocarcinoma remains controversial.
Debate also continues regarding the value of preopera-
tive biliary drainage in patients with biliary malignancies.
Prospective randomised trials, which have been underpow-
ered and have included more patients with distal
obstruction, have failed to demonstrate a benefit for preop-
erative biliary drainage. In addition, large retrospective
series of patients undergoing pancreatoduodenectomy have
documented increased infective and/or pancreatic compli-
cations. Nevertheless, patients with proximal biliary
malignancies have higher bilirubin levels and intrabiliary
pressures and are more prone to cholangitis. Thus, the
relative value of preoperative biliary drainage in patients
with perihilar biliary malignancy with and without the
atrophy/hypertrophy complex still needs to be determined.
Over the past decade, the concept of preoperative por-
tal vein embolisation (PVE) for patients undergoing major
liver resection has been introduced and adopted in many
hepatobiliary units. One prospective randomised trail has
not shown any advantage of preoperative PVE in patients
with a normal liver undergoing a right hepatic lobectomy.
On the other hand, morbidity was reduced in the subset of
patients with hepatic fibrosis. However, the exact role and
timing of preoperative PVE in patients with obstructive
jaundice due to a perihilar cholangiocarcinoma or gall-
bladder cancer has yet to clarified. Should these patients
undergo preoperative PVE? If so, should biliary drainage be
performed first? Should the period between PVE and oper-
ation be longer or shorter with jaundice, malignancy and/or
cholangitis? All these questions have yet to be adequately
answered.
As with all tumours, the results of resection of gallbladder
cancer and cholangiocarcinoma are best when the margins
are negative microscopically, i.e. R0. This goal can be achieved
with an ‘extended cholecystectomy’ in patients with stage I
and II gallbladder cancer. However, in more advanced stage
gallbladder malignancies, especially those presenting with
obstructive jaundice, the ability to achieve an R
0
resection
is significantly reduced. Similarly, the likelihood of accom-
plishing an R0 resection is greater with intrahepatic and
distal cholangiocarcinoma lesions rather than with perihi-
lar. There has been general acceptance of the need to
perform a liver resection, including the caudate lobe espe-
cially with left-sided biliary tumours, to achieve an R
0
resection. The importance of minimising blood loss during
resection has also become a basic principle. However, sur-
geons vary considerably on technical details – such as the
use of the ultrasonic dissector, the harmonic scalpel,
Ligaclips – as well as on temporary vascular occlusion tech-
niques such as the Pringle manoeuvre, total vascular
exclusion and ischaemic preconditioning.
Several groups have demonstrated that resection of
portions of the portal vein or the head of the pancreas to
achieve an R
0
resection can be performed. However, an
overall analysis of these extensive operations suggests that
morbidity and mortality is increased and long-term survival
is decreased compared with patients with smaller tumours
undergoing more conventional operations. Similarly, the
results of liver transplantation for biliary malignancies have
been disappointing. Whether the results of transplantation
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will be improved in carefully selected patients treated with
pre-operative chemoradiation remains to be seen.
With respect to palliative treatment, multiple options
continue to be advocated by surgeons, interventional
radiologists and endoscopists. In patients with locally unre-
sectable perihilar tumours some surgeons favour a segment
III bypass, whereas others prefer placement of transhepatic
stents into a Roux-en-Y hepaticojejunostomy anastomosed
below the tumour. In the absence of the atrophy/hypertro-
phy complex, most experts advocate drainage of both
hepatic lobes. Many also agree that this goal is more easily
achieved in proximal tumours by the percutaneous as
opposed to the endoscopic route. In recent years metal
stents have tended to replace plastic stents for palliation;
however, with more proximal tumours the application of
two or more metal stents can be technically difficult.
Although several retrospective studies have been pub-
lished, no prospective randomised trials comparing surgical,
percutaneous or endoscopic palliation have been reported. 
To date, chemotherapy, radiotherapy, chemoradiation
and photodynamic therapy have not been proven to pro-
long survival in patients with gallbladder or bile duct
malignancies. Many retrospective studies have suggested
that one or more of these treatments is beneficial. However,
treated patients generally have smaller, often resected
tumours and good performance status, whereas untreated
patients usually have larger, unresected and sometimes
metastatic tumours and poor performance status. Thus,
these non-randomised studies favour whatever treatment
has been applied. Several innovative methods to deliver
chemotherapy (arterial or chemo-embolisation) or radio-
therapy (intra-operative, brachytherapy or conformal)
have been introduced. However, no prospective ran-
domised data support any of these options.
In summary, modest progress has been made in the past
20 years in our ability to diagnose, stage and safely resect
biliary malignancies. However, major improvements still
need to be made in classification, understanding the patho-
genesis, early diagnosis, pre-operative preparation,
intra-operative management, determining the best meth-
ods for palliation and understanding the role of adjuvant
therapy. To accomplish these goals, worldwide cooperation
will be needed to study high-risk patients and the rare pop-
ulations with a very high incidence. These efforts should
reveal the multiple genetic and environmental factors that
cause these devastating malignancies. Armed with this
information, hepatobiliary experts of the future should be
able to establish preventive strategies and early diagnosis.
Similarly, a multidisciplinary approach will be required to
achieve the best treatment and/or palliation for individual
patients. Because of their rarity, multicontinental trials will
be necessary to determine the role of adjuvant therapy for
biliary malignancies. Thus, dramatic progress will be possible
over the next two decades if we all work together.
Henry A Pitt
Milwaukee,WI, USA
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